ACTUATE THERAPEUTICS, INC.

Registration (IPO) statement under Securities Act of 1933

General form for quarterly reports under Section 13 or 15(d)

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Draft registration statement (confidential submission)

Submission of Matters to a Vote of Security Holders

General form for quarterly reports under Section 13 or 15(d)

Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans

Regulation FD Disclosure

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Additional Information for Proxy Statement/ Votes

Beneficial ownership report for a passive holder of more than 5% (Schedule 13G) (amendment)

Annual Report Scanned (Paper)

Additional Information for Proxy Statement/ Votes

Definitive Proxy Statement

Annual report pursuant to Section 13 or 15(d)

Regulation FD Disclosure

Beneficial ownership report for a passive holder of more than 5% (Schedule 13G)

Entry into a Material Definitive Agreement

Prospectus Supplement for Primary Offering

Other Events

General form for quarterly reports under Section 13 or 15(d)

Entry into a Material Definitive Agreement

Prospectus Supplement for Primary Offering

Prospectus Supplement for Primary Offering

Notice of Effectiveness

Correspondence with the SEC

Correspondence with the SEC

Registration statement under Securities Act of 1933

Letter from the SEC

Draft registration statement (confidential submission)

General form for quarterly reports under Section 13 or 15(d)

Notice of Effectiveness

Prospectus Supplement for Primary Offering

Correspondence with the SEC

Letter from the SEC

Registration (IPO) statement under Securities Act of 1933

<ITEMS>06b

Beneficial ownership report for a holder of more than 5% (Schedule 13D) (amendment)

Entry into a Material Definitive Agreement

Regulation FD Disclosure

Regulation FD Disclosure

Submission of Matters to a Vote of Security Holders

General form for quarterly reports under Section 13 or 15(d)

Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans

Other Events

Prospectus Supplement for Primary Offering

Notice of Effectiveness

Correspondence with the SEC

<ITEMS>06b

Additional Information for Proxy Statement/ Votes

Definitive Proxy Statement

Letter from the SEC

Entry into a Material Definitive Agreement

Registration (IPO) statement under Securities Act of 1933

Annual report pursuant to Section 13 or 15(d)

Other Events

Regulation FD Disclosure

General form for quarterly reports under Section 13 or 15(d)

Regulation FD Disclosure

General form for quarterly reports under Section 13 or 15(d)

4.01,9.01

5.02,5.03,8.01,9.01

Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans

No description available

Post-effective amendment filed solely to add exhibits

Prospectus Supplement with Pricing Information

Correspondence with the SEC

Correspondence with the SEC

Registration of Securities on Exchange (amendment)

Notice of Effectiveness

Correspondence with the SEC

Correspondence with the SEC

Correspondence with the SEC

Correspondence with the SEC

Correspondence with the SEC

Correspondence with the SEC

SCHMITT DANIEL M

THOMSON TODD S

Fletcher Aaron G.L.

Huber Martin H. Jr.

Keyes Jason A

RONNEBERG AMY L

Sawhney Roger

Zabrowski Dan

Huber Martin H. Jr.

Mazar Andrew Paul

LYTLE PAUL J

SCHMITT DANIEL M

SCHMITT DANIEL M

THOMSON TODD S; Kairos Venture Partners II, L.P.

Kairos Venture Partners II, L.P.

Bios Clinical Opportunity Fund, LP; BP Directors, LP; Bios 2024 Co-Invest, LP; Bios Equity COF, LP

BIOS Fund II NT, LP; BIOS Fund I, LP; BIOS Fund I QP, LP; BIOS Fund II, LP; BIOS Fund II QP, LP; Kreis Leslie W.; Cavu Management, LP; Cavu Advisors, LLC; Bios Equity Partners II, LP; Bios Equity Partners, LP